GlassScriptPhysician profile
William A Bohonyi
NPI 1851365753
$6,442.08
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,052 · 2020: $1,499 · 2021: $1,838 · 2022: $677 · 2023: $264 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,760.87 | 2019-2023 | Ubrelvy, Qulipta, Orilissa |
| Novo Nordisk INC | $805.58 | 2019-2022 | |
| Amgen INC. | $644.28 | 2019-2021 | |
| Pfizer INC. | $287.97 | 2020-2023 | |
| Therapeuticsmd, INC. | $236.71 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $236.14 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $231.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.41 | 2019-2022 | |
| Lupin INC. | $178.17 | 2019-2021 | |
| Hologic Sales and Service, LLC | $174.01 | 2019 | |
| Merck Sharp & Dohme LLC | $137.96 | 2019-2022 | |
| Baudax Bio INC. | $130.69 | 2020 | |
| Exeltis, USA INC. | $123.51 | 2020-2022 | |
| Astellas Pharma US INC | $121.15 | 2019-2021 | |
| Duchesnay USA Incorporated | $113.54 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $101.81 | 2021 | |
| Allergan, INC. | $100.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $90.15 | 2024 | Dupixent |
| Sage Therapeutics, LLC | $87.08 | 2020-2021 | |
| Ethicon US, LLC | $86.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.07 | 2019-2020 | |
| Minerva Surgical, INC | $68.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $60.22 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $56.48 | 2021 | |
| Avion Pharmaceuticals | $53.98 | 2019-2021 | |
| Eisai INC. | $49.30 | 2019-2020 | |
| Organon LLC | $35.22 | 2021-2022 | |
| Mission Pharmacal Company | $30.88 | 2019-2020 | |
| Axonics, INC. | $27.02 | 2021 | |
| Galderma Laboratories, L.P. | $23.12 | 2024 | |
| Dysis Medical, INC. | $22.38 | 2019 | |
| Mayne Pharma Commercial LLC | $21.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.31 | 2022 | |
| Myovant Sciences INC. | $16.52 | 2022 | |
| Acessa Health INC. | $15.85 | 2019 | |
| Alydia Health | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bohonyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.